The AAPM 2020 educational program will be available in fall 2019. In the meantime browse 2019 meeting sessions and speakers to get a sense of the premier pain education offered during the AAPM Annual Meeting & Preconferences. Access recordings of past meeting sessions on demand.

Lunch CME Satellite Symposia

Noon–1:30 pm Thursday, March 7


Noon-12:30 pm

AAPM Lunch Provided

12:30-1:30 pm

Recognition and Management of Migraine in an Era of Expanding Options for Acute Treatment and Prevention

Educational Objectives

  • Apply established screening tools and criteria for migraine diagnosis in clinical practice.
  • Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine.
  • Cite updated evidence on available and emerging therapies for the prevention of migraine.
  • Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.


Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. During this PeerView Live lunch symposium, after briefly reviewing how migraine can be identified in clinical practice, experts in the management of this neurologic disorder will discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice.

Register now.


CME Information

Target Audience

This activity has been designed to meet the educational needs of pain management specialists, headache specialists, neurologists, primary care physicians, internal medicine physicians, nurses, and other clinicians involved in the management of migraine.

Requirements for Successful Completion

In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/CNE credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test.

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.


The information provided at this CME/MOC/CNE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.


Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).


This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.


This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.


Stewart J. Tepper, MD, FAHS

Robert P. Cowan, MD, FAAN, FAHS